SCHEMBL2641797

SCHEMBL2641797

CN(C)c1ccc(CP(=O)(O)O)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.52
TSHR P16473 3/20 0.52
MAPK1 P28482 2/20 0.52
CYP3A4 P08684 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
PGK1 P00558 5/20 0.50
PGK2 P07205 5/20 0.50
ENPP2 Q13822 2/20 0.50
HDAC1 Q13547 2/20 0.47
HDAC6 Q9UBN7 1/20 0.47
HSD17B10 Q99714 2/20 0.46
ALOX15 P16050 1/20 0.46
KDM4E B2RXH2 2/20 0.44
HTT P42858 1/20 0.44
HPGD P15428 2/20 0.43
MAPT P10636 1/20 0.43
GAA P10253 2/20 0.41
DGAT2 Q96PD7 1/20 0.41
HDAC4 P56524 1/20 0.41
G6PD P11413 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1617420 0.82 PGK1 (0.67) PGK1PGK2ENPP2DGAT2SMN1; SMN2
SCHEMBL16335457 0.81 PGK1 (0.46) ALDH1A1MAPK1PGK1PGK2ENPP2
SCHEMBL16353250 0.79 PGK1 (0.50) ALDH1A1TSHRPGK1PGK2ENPP2
SCHEMBL9512466 0.78 ENPP2 (0.42) PGK1PGK2ENPP2DGAT2
SCHEMBL16353269 0.76 PGK1 (0.49) ALDH1A1CYP3A4TDP1PGK1PGK2
SCHEMBL11304410 0.76 ENPP2 (0.60) ALDH1A1PGK1PGK2ENPP2DGAT2
SCHEMBL916486 0.76 PGK1 (0.61) TSHRPGK1PGK2ENPP2MAPT
SCHEMBL9407120 0.75 PGK1 (0.59) PGK1PGK2ENPP2
SCHEMBL12960342 0.75 HRH3 (0.63) ALDH1A1TSHRPGK1PGK2ENPP2
SCHEMBL126802 0.74 ENPP2 (0.46) PGK1PGK2ENPP2HDAC6HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3013787-B1 TRANSITION-METAL-FREE N-ARYLATION OF TERTIARY AMINES USING ARYNES COUNCIL SCIENT IND RES (IN) 2017-08-02 EP claimed
US-9650329-B2 Transition-metal-free N-arylation of tertiary amines using arynes COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-05-16 US claimed
US-20160137587-A1 TRANSITION-METAL-FREE N-ARYLATION OF TERTIARY AMINES USING ARYNES COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2016-05-19 US claimed
EP-3013787-A1 TRANSITION-METAL-FREE N-ARYLATION OF TERTIARY AMINES USING ARYNES Council of Scientific & Industrial Research (IN) 2016-05-04 EP claimed
WO-2014207761-A1 TRANSITION-METAL-FREE N-ARYLATION OF TERTIARY AMINES USING ARYNES COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2014-12-31 WO claimed
EP-3013787-B1 TRANSITION-METAL-FREE N-ARYLATION OF TERTIARY AMINES USING ARYNES COUNCIL SCIENT IND RES (IN) 2017-08-02 EP disclosed
US-9650329-B2 Transition-metal-free N-arylation of tertiary amines using arynes COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-05-16 US disclosed
US-20160137587-A1 TRANSITION-METAL-FREE N-ARYLATION OF TERTIARY AMINES USING ARYNES COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2016-05-19 US disclosed
EP-3013787-A1 TRANSITION-METAL-FREE N-ARYLATION OF TERTIARY AMINES USING ARYNES Council of Scientific & Industrial Research (IN) 2016-05-04 EP disclosed
WO-2014207761-A1 TRANSITION-METAL-FREE N-ARYLATION OF TERTIARY AMINES USING ARYNES COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2014-12-31 WO disclosed
WO-2011141515-A1 DIAGNOSTIC AGENTS FOR AMYLOID BETA IMAGING BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2011-11-17 WO disclosed
US-6090969-A REACTING AN OPTICALLY ACTIVE BINAPHTHOL WITH AN ALKALI METAL ALUMINUM HYDRIDE OR A DIALKYLALUMINUM HYDRIDE AND AN ALKALI OR ALKALINE EARTH METAL BASE NAGASE AND CO., LTD. (JP) 2000-07-18 US disclosed
US-5847186-A Process for preparing asymmetric compound by using metal complex NAGASE & COMPANY, LTD. (JP) 1998-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160137587-A1 TRANSITION-METAL-FREE N-ARYLATION OF TERTIARY AMINES USING ARYNES CDK6, NEK6, MCM6 ALDH1A1 1357/4885TSHR 1941/4885MAPK1 2557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.